Diagnostics Solutions Strategic Priorities slide image

Diagnostics Solutions Strategic Priorities

Supporting patient journeys with our oncology pipeline Pharma partner of choice, driving personalised healthcare Roche +2 Screening Diagnosis & Classification Prognosis¹ Therapy selection2 +3 +21 250+ +5 +27 +4 380 Monitoring/Surveillance +5 +10 +7 13 LUJUL 3 +2 +1 1 1 +4 8 5 +1 2 +2 1 1 +1 +1 10 7 5 3 1 +1 +1 wwww H IA IHC PCR Algorithms IA IHC PCR Algorithms IA IHC NGS Algorithms IA (CA 19-9) (Ki67) (EGFR) (CA 19-9) (Ki67) (EGFR) (CA 19-9) (Ki67) (CA 19-9) IHC (Ki67) PCR (EGFR) NGS Algorithms IA (CA 19-9) PCR (EGFR) NGS Algorithms Immunoassay (IA) 1 Predicting the likely or expected development of a disease 2 On-label CDx indications Decision support: NAVIFY Mutation Profiler, NAVIFY Tumor Board, NAVIFY guidelines + Patient Journey, Guidelines adherence tracking, quality reporting, therapy matching Immunohistochemistry (IHC) H Next Gen Sequencing (NGS) MIX 65 Polymerase Chain Reaction (PCR) Algorithms
View entire presentation